Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of LIVER-limited HepatoCellular Carcinoma (HCC) in Patients With Preserved Liver Function by IRreversible Electroporation: A Prospective, International, Multi-centre Cohort Study

NCT07192731 is registered in ClinicalTrials.gov with Angiodynamics, Inc. as lead sponsor.

NCT NCT07192731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07192731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of LIVER-limited HepatoCellular Carcinoma (HCC) in Patients With Preserved Liver Function by IRreversible Electroporation: A Prospective, International, Multi-centre Cohort Study
Lead sponsor
Angiodynamics, Inc.
Phase
Not applicable
Overall status
Not yet recruiting
Start date
February 28, 2026
Completion date
February 28, 2029
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc), liver ablation, liver cancer, adult